Pyxis Oncology, Inc. — Q1 2023 Form 10-Q
Business context and reporting period. Unaudited results for the three months ended March 31, 2023. Pyxis Oncology is a clinical-stage oncology company with no approved products and no revenue. Its lead candidates, PYX-201 and PYX-106, entered Phase 1 development; the company says it is prioritizing these programs and has paused preclinical development of PYX-203 and PYX-102.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0; no revenue generated to date |
| Research and development expense | $11.9 million | $20.1 million, down $8.2 million |
| General and administrative expense | $9.1 million | $11.3 million, down $2.3 million |
| Total operating expenses | $21.0 million | $31.4 million, down $10.4 million |
| Net loss | $19.2 million; $0.54 per share | $31.4 million; $0.97 per share |
| Operating cash flow | $(26.8) million | $(27.7) million |
| Cash, cash equivalents and short-term investments | $149.3 million at March 31, 2023 | $179.3 million cash and cash equivalents at December 31, 2022; no marketable securities then |
At March 31, cash and cash equivalents were $53.1 million and short-term U.S. Treasury securities were $96.3 million; restricted cash of $1.5 million is additional and is not included in the $149.3 million liquidity figure. Total assets were $182.8 million, total liabilities $30.6 million, and stockholders’ equity $152.2 million. The filing reports no debt. Gross margin is not meaningful because there was no revenue.
Investing cash outflow was $99.4 million, primarily $95.0 million of Treasury purchases and $4.4 million of property and equipment. Thus, the $126.2 million decline in cash, cash equivalents and restricted cash largely reflects moving funds into investments as well as operating outflows, rather than operating burn alone.
Material changes and unusual items
- R&D expense fell mainly because Q1 2022 included a $10.0 million Biosion license fee; lower contract manufacturing and preclinical costs also contributed. These reductions were partly offset by higher personnel costs and clinical-trial spending.
- G&A decreased primarily because the prior-year quarter had higher legal, recruiting, professional and consulting costs.
- Interest and investment income increased to $1.7 million from $9,000, reflecting higher rates and discount accretion on Treasury securities; the company also recorded $38,000 of sublease income.
- Q1 operating cash outflow included a $13.3 million decrease in accrued expenses, including an $8.0 million payment to Pfizer under the amended license agreement. The company also issued 1,811,594 common shares to Pfizer, valued at $5.0 million.
- A March 2023 stock-option repricing generated $1.1 million of incremental stock-based compensation, of which $0.7 million was expensed in Q1. Stock-based compensation overall was $4.9 million.
Outlook, risks and contingencies
- Management estimates existing cash, cash equivalents and short-term investments will fund operating and capital requirements into the first half of 2025. A separate liquidity disclosure says the resources are expected to cover at least twelve months from issuance. Both estimates depend on assumptions and could change; additional capital may be needed.
- The company expects operating losses and expenses to increase as it advances clinical development. It has no product revenue and may never achieve profitability.
- PYX-201’s Phase 1 trial began dosing in Q1; preliminary data were anticipated in early 2024. PYX-106 sites were being activated and patients screened; dosing was anticipated in Q2 2023, with preliminary data anticipated in late 2023. In May 2023, after quarter-end, PYX-201 received FDA Orphan Drug Designation for pancreatic cancer.
- After quarter-end, the company sold 1,001,208 shares through its ATM program on April 3–4, raising $6.3 million gross and paying $0.2 million in commissions.
- Key risks include early-stage clinical and regulatory uncertainty, reliance on third-party manufacturers and service providers, competition, intellectual-property and license-agreement risks, and the need for additional financing. The company disclosed up to $665 million in potential development, regulatory and commercial milestones to Pfizer for the first four licensed ADCs, plus royalties and other contingent obligations; these are not current fixed payments.
- Net fixed lease obligations, net of sublease payments and tenant improvement allowance, totaled $27.3 million. The company remains jointly and severally liable under its head lease. It reported no material legal proceedings and no significant cancellable operating commitments.
Important facts for investors to verify
- Whether clinical enrollment, safety, and data-generation timelines for PYX-201 and PYX-106 remain on track, and whether reported preliminary data are subsequently confirmed.
- Whether the stated runway into the first half of 2025 remains achievable as clinical, manufacturing and capital needs evolve.
- Future operating cash burn and the effect of additional ATM or other financing on liquidity and share dilution.
- Potential dilution from equity awards: 5.7 million options and 5.7 million unvested restricted awards and units were outstanding at March 31, 2023.
- Progress against license obligations and the scale and timing of contingent milestones, royalties and sublease receipts.